JPRN-UMIN000022155
Completed
未知
Effect of SGLT-2 inhibitors on Hepatic Steatosis and Fibrosis Estimated by using Fibroscan with Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease - STHENIC trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Type 2 Diabetes Suffering from Non-alcoholic Fatty Liver Disease
- Sponsor
- Dokkyo Medical University
- Enrollment
- 60
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Type 1 diabetes 2\) Severe diabetic complications such as ketoacidosis 3\) Severe renal dysfunction(estimated glomerular filtration rate \[eGFR] \< 30 mL/min/) 4\) Pregnant or nursing women and those who might be pregnant 5\) Chronic heart failure, 6\) Haemodialysis, 7\) A history of stroke and cardiovascular events, 8\) Any patient whom the investigator judged to be inappropriate for this study. Patients were given detailed explanations of the study protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic NephropathyEffect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic NephropathyNCT06668753Assiut University114
Completed
Not Applicable
Effect of high dose SGLT-2 inhibitor on fatty livertype2 diabetes/fatty liverJPRN-UMIN000047270Konuma Internal medicine Gastroenterology Clinic directer20
Not yet recruiting
Phase 3
The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes MellitusFatty Liver, NonalcoholicNCT06117137Sohag University150
Not yet recruiting
Phase 3
Effect of Saroglitazar in Non alcoholic fatty liver diseaseHealth Condition 1: K77- Liver disorders in diseases classified elsewhereCTRI/2024/03/063735o sponsor
Completed
Not Applicable
Effects of canagliflozin on the hepatic steatosis, adipose tissue and skeletal muscle in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease / non-alcoholic steatohepatitisJPRN-UMIN000018814Yokohama City University Graduate School of Medicine20